2024-518857-41-00
尚未招募
4 期
Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden
概览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 150,000
- 试验地点
- 21
- 主要终点
- Uptake of HPV vaccine in eligible women, by county and age strata.
概览
简要总结
The study aims to evaluate whether organised, concomitant HPV vaccination and HPV screening offered by the Swedish cervical screening program to all resident women aged 23-25 will result in a more rapid elimination of HPV infection in Sweden. This objective will be examined at the population level.
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Eligible women will include resident women within the age range of 23- 25 due for invitation to organised cervical cancer screening who consent to participate in the study.
排除标准
- •Known history of severe allergic reaction or hypersensitivty to any of the components of the HPV vaccine. For GARDASIL 9: Amorphous aluminium hydroxyphosphate sulphate adjuvant, Sodium chloride, L-histidine, Polysorbate 80 or Sodium borate.
- •Known history of immune-related disorders.
- •Current acute severe febrile illness, except for minor infections such as a cold, mild upper respiratory infection or low-grade fever.
- •Administration of immunoglobulin or blood-derived products within 6 months prior to scheduled HPV vaccine first dose.
- •Current pregnancy (reported).
- •Hysterectomized women.
结局指标
主要结局
Uptake of HPV vaccine in eligible women, by county and age strata.
Uptake of HPV vaccine in eligible women, by county and age strata.
次要结局
- Compliance with HPV vaccine administration Schedule.
研究者
Joakim Dillner
Scientific
Region Stockholm
研究点 (21)
Loading locations...
相似试验
尚未招募
不适用
VulVaccin study2023-506792-94-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)498
进行中（未招募）
1 期
Women aged 23-25 that are invited and participating in the organised cervical screening program of Sweden will be offered 2 doses of Gardasil 9 at their first and second visit, with 3 years apart. This in line with WHO's directives to eliminate cervical cancer worldwide.HPV infection and related diseases, such as cervical intraepithelial neoplasia grade 2 and 3 and cervical cancer.MedDRA version: 21.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10056576Term: Cervical intraepithelial neoplasiaSystem Organ Class: 100000004872Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-001169-34-SERegion Stockholm150,000
尚未招募
2 期
Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPVNCT07303751Institut d'Investigació Biomèdica de Bellvitge80
招募中
4 期
Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in SwedenHPV InfectionCIN 2/3Cervical CancerNCT04910802Miriam Elfström150,000
进行中（未招募）
不适用
Self-sampling for HPV ScreeningNCT07273383Université de Sherbrooke1,000